The Role of FAS-Mediated Apoptosis in Chronic Myelogenous Leukemia

References

• Heisterkamp N., Stam K., Groffen J., De Klein A., Grosveld G. Structural organization of the ber gene and its role in the Ph1 translocation. Nature 1985; 315: 758–761
   PubMed Web of Science ®Google Scholar
• Shtiveiman E., Lifshitz B., Gale R. P., Roe B. A., Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986; 47: 277–284
   PubMed Web of Science ®Google Scholar
• Clark S. S., McLaughin J., Timmonis M, Pendergast A. M., Bin-Neriah Y., Dow L., Rovera G., Smith S. D., Witte O. N. Expression of a distinctive BCR-ABL oncogene in Phi-positive acute lymphocytic leukemia (ALL). Science 1988; 238: 775–778
   Web of Science ®Google Scholar
• Pane F., Frigeri F., Sindona M., Luciano L., Ferrara F., Cimino R., Meloni G., Saglio G., Salvatore F., Rotoli B. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88: 2410, 1996
   PubMed Web of Science ®Google Scholar
• Li S., Ilaria R. L., Jr, Million R. P., Daley G. Q., Van Elten R. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 1999; 189: 1399–1412
   PubMed Web of Science ®Google Scholar
• Lugo T. G., Pendergast A. M., Muller A. J., Witte O. N. Tyrosine kinase and transformation poteney of bcr-abl oncogene products. Science 1990; 250: 559–562
   PubMed Web of Science ®Google Scholar
• Heisterkamp N., Jenster G., Ten Hoeve J., Zovich D., Pat-Tengale P. K., Groffen J. Acute leukemia in bcr/abl transgenic mice. Nature 1990; 344: 251–253
   PubMed Web of Science ®Google Scholar
• Daley G. Q. Animal models of BCR/ABL-induced leukemias. Leuk. Lymphoma 1993; 11: 57–60, Suppl. 1
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P2l0bcr/abl protein. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 9312–9316
   PubMed Web of Science ®Google Scholar
• Gishizky M. L., Witte O. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 1992; 256: 836–839
   PubMed Web of Science ®Google Scholar
• Sawers C. L. Chronic myeloid leukemia. N. Engl. J. Med. 1999; 340: 1330–1340
   PubMed Web of Science ®Google Scholar
• Pendergast A. M., Quilliam L. A., Cripe L. D., Bassing C. H., Dai Z., Li N., Batzer A., Rabun K. M., Dcr C. J., Schlessinger J., Gishizky M. L. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175–185
   PubMed Web of Science ®Google Scholar
• Lowenstein E. J., Daly R. J., Batzer A. G., Margolis W. L., Lammers R., Ullrich A., Skolnik E. Y., Bar-Sagi D., Schlessinger J. The SH2 and SH3 domain-containing protein Grb2 links receptor tyrosine kinase to Ras signaling. Cell 1992; 70: 431–432
   PubMed Web of Science ®Google Scholar
• Tauchi T., Boswell H. S., Leibowitz D., Broxmeyer H. E. Coupling between p210bcr-abl and She and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to Ras activation pathway. J. Exp. Med. 1994; 179: 167–175
   PubMed Web of Science ®Google Scholar
• Sattler M., Salgia R. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia 1998; 12: 637–644
   PubMed Web of Science ®Google Scholar
• Kolibaba K. S., Bhat A., Heaney C., Oda T., Druker B J. CRKL binding to BCR-ABL and BCR-ABL transformation. Leuk. Lymphoma 1999; 33: 119–126
   PubMed Web of Science ®Google Scholar
• Carpino N., Wisniewski D., Strife A., Marshak D., Kobayashi R., Stillman B., Clarkson B. p62(dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous progenitor cells. Cell 1997; 88: 197–204
   PubMed Web of Science ®Google Scholar
• Matsuguchi T., Inhorn R. C., Carlesso N., Xu C, Druker B., Griffin J. D. Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. EMBO J. 1995; 14: 257–265
   PubMed Web of Science ®Google Scholar
• Bhat A., Kolibaba K., Oda T., Ohno-Jones S., Heaney C., Druker B. J. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells. J. Biol. Chem. 1997; 272: 16170–16175
   PubMed Web of Science ®Google Scholar
• Afar D. E., Han L., McLaughlin J., Wong S., Dhaka A., Parmar K., Rosenberg N., Witte O. N., Colicelli J. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 1997; 6: 773–782
   PubMed Web of Science ®Google Scholar
• Salgia R., Brunkhorst B., Pisick E., Li J. L., Lo S. H., Chen L. B., Griffin J. D. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 1995; 11: 1149–1155
   PubMed Web of Science ®Google Scholar
• Mandanas R. A., Leibowitz D. S., Gharehbaghi K., Tauchi T., Burgess G. S., Miyazawa K., Jayaram H. N., Boswell H. S. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993; 82: 1838–1847
   PubMed Web of Science ®Google Scholar
• Skorski T., Wlodarski P., Daheron L., Salomoni P., Nieborowska-Skorska M., Majewski M., Wasik M., Calabretta B. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc. Natl. Acad. Set. USA 1998; 95: 11858–11862
   PubMed Web of Science ®Google Scholar
• Salomoni P., Wasik M. A., Riedel R. F., Reiss K, Choi J. K., Skorski T., Calabretta B. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J. Exp. Med. 1998; 187: 1995–2007
   PubMed Web of Science ®Google Scholar
• Shi C. S., Tuscano J. M., Witte O. N., Kehrl J. H. GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway. Blood 1999; 93: 1338–1345
   PubMed Web of Science ®Google Scholar
• Raitano A. B., Halpern J. R., Hambuch T. M., Sawyers C. L. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA 1995; 92: 11746–11750
   PubMed Web of Science ®Google Scholar
• Calabretta B., Skorski T. BCR/ABL regulation of PI-3 kinase activity. Leuk. Lymphoma 1996; 23: 473–476
   PubMed Web of Science ®Google Scholar
• Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J. K., Trotta R., Wlodarski P., Perrotti D., Chan T O., Wasik M. A., Tsichlis P. N., Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997; 16: 6151–6161
   PubMed Web of Science ®Google Scholar
• Amarante-Mendes G. P., McGahon A. J., Nishioka W. K., Afar D. E., Witte O. N., Green D. R. Bcl-2 independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with up-regulation of Bcl-xL. Oncogene 1998; 16: 1383–1390
   PubMed Web of Science ®Google Scholar
• Deininger M. W., Goldman J. M. Chronic myeloid leukemia. Curr. Opin. Hematol. 1998; 5: 302–308
   PubMedGoogle Scholar
• Majewski M., Nieborowska-Skorska M., Salomoni P., Slupianek A., Reiss K., Trotta R., Calabretta B., Skorski T. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 1999; 59: 2815–2819
   PubMed Web of Science ®Google Scholar
• Sawyers C. L., Callahan W., Witte O. N. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992; 70: 901–910
   PubMed Web of Science ®Google Scholar
• Reuther J. Y., Reuther G. W., Cortez D., Pendergast A. M., Baldwin A. S., Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998; 12: 968–81
   PubMed Web of Science ®Google Scholar
• Carlesso N., Frank D. A., Griffin J. D. Tyrosyl phosporilation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 1996; 183: 247–254
   Web of Science ®Google Scholar
• Nieborowska-Skorska M., Wasik M. A., Slupianek A., Salomoni P., Kitamura T., Calabretta B., Skorski T. Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Sre homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 1999; 189: 1229–1242
   PubMed Web of Science ®Google Scholar
• Skorski T., Nieborowska-Skorska M., Barletta C., Malaguarnera L., Szczylik C, Chen T. S., Lange B., Calabretta B. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligonucleotides combined with mafosfamide. J. Clin. Invest. 1993; 92: 194–202
   PubMed Web of Science ®Google Scholar
• De Fabritiis P., Petti M. C., Montefusco E., De Propris M. S., Sala R., Bellucci R., Mancini M., Lisci A., Bonetto R, Geiser T., Calabretta B., Mandelli F. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998; 91: 3156–3162
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C., Dotti G., Mangoni L., Regazzi E., Garau D., Rizzo M. T., Savoldo B., Rizzoli V. Selection of myeloid progenitors lacking BCR-ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 1996; 88: 3091–1996
   PubMed Web of Science ®Google Scholar
• Druker B. J., Tamura S., Buchdunger E., Ohno S., Segal G. M., Fanning S., Zimmermann J., Lydon N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996; 2: 561–566
   PubMed Web of Science ®Google Scholar
• Deininger M. W., Goldman J. M., Lydon N., Melo J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691–3698
   PubMed Web of Science ®Google Scholar
• Le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., Formelli F., Gambacorti-Passerini C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 1999; 91: 163–168
   PubMed Web of Science ®Google Scholar
• Sawyers C. L., McLaughlin J., Witte O. N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr/Abl oncogene. J. Exp. Med. 1995; 181: 307–313
   PubMed Web of Science ®Google Scholar
• Skorski T., Kanakaraj P., Nieborowska-Skorska M., Ratajczak M. Z., Wen S. C., Zon G., Gewirtz A. M., Perussia B., Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726–736
   PubMed Web of Science ®Google Scholar
• Dickens M, Rogers J. S., Cavanagh J., Raitano A., Xia Z., Halpem J. R., Greenberg M. E., Sawyers C. L., Davis R. J. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997; 277: 693–696
   PubMed Web of Science ®Google Scholar
• Afar D. E.H., Goga A., McLaughlin J., Witte O. N., Sawyers C. L. Differential complementation of Bcr/Abl point mutants with c-Myc. Science 1994; 264: 424–426
   PubMed Web of Science ®Google Scholar
• Skorski T., Kanakaraj P., Ku D. H., Nieborowska-Skorska M., Canaani E., Zon G., Perussia B., Calabretta B. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J. Exp. Med. 1994; 179: 1855–1865
   PubMed Web of Science ®Google Scholar
• Cortez D., Stoica G., Pierce J. H., Pendergast A. M. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 1996; 13: 2589–2594
   PubMed Web of Science ®Google Scholar
• Selleri C., Maciejewski J. P., Sato T., Young N. S. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 1996; 87: 4149–4157
   PubMed Web of Science ®Google Scholar
• Wickremasinghe R. G., Hoffbrand A. V. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood 1999; 93: 3587–3600
   PubMed Web of Science ®Google Scholar
• Hannun Y. A. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845–1853
   PubMed Web of Science ®Google Scholar
• Friesen C., Herr I., Krammer P. H., Debatin K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 1996; 2: 574–577
   PubMed Web of Science ®Google Scholar
• Reed J. C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 1999; 11: 68–75
   PubMedGoogle Scholar
• Landowski T. H., Gleason-Guzman M. C., Dalton W. S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997; 89: 1854–1861
   PubMed Web of Science ®Google Scholar
• McGahon A., Bissonnette R., Schmitt M., Cotter K. M., Green D. R., Cotter T. G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179–1187
   PubMed Web of Science ®Google Scholar
• Bedi A., Zehnbauer B. A., Barber J. P., Sharkis S. J., Jones R. J. Inhibition of apoptosis by BCR-ABL in cbronic myelogenous leukemia. Blood 1994; 83: 2038–2044
   PubMed Web of Science ®Google Scholar
• Bedi A., Berber J. P., Bedi G. C., El-Deiry W. S., Sidransky D., Vala M. S., Akhtar A. J., Hilton J., Jones R. J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148–1158
   PubMed Web of Science ®Google Scholar
• McGahon A., Nishioka W. K., Martin S. J., Mahboubi A., Cotter T. G., Green D. R. Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. 1995; 270: 22625–22631
   PubMed Web of Science ®Google Scholar
• Cotter T G. BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Leuk. Lymphoma 1995; 18: 231–236
   PubMed Web of Science ®Google Scholar
• Yuan Z-M., Huang Y., Whang Y., Sawyers C., Weichselbaum R., Kharbanda S., Kufe D. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 1996; 382: 272–274
   PubMed Web of Science ®Google Scholar
• McGahon A., Brown D. G., Martin S. J., Amarante-Mendes G. P., Cotter T. G., Cohen G. M., Green D. R. Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: Characterization of apoptotic death. Cell Death and Different. 1997; 4: 95–104
   PubMed Web of Science ®Google Scholar
• Selleri C., Sato T., Del Vecchio L., Luciano L., Barrett A. J., Rotoli B., Young N. S., Maciejewski J. P. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 1997; 89: 957–964
   PubMed Web of Science ®Google Scholar
• Selleri C., Maciejewski J. P., Pane F., Luciano L., Raiola A. M., Mostarda I., Salvatore F., Rotoli B. Fas-mediated modulation of BCR/ABL in chronic myelogenous leukemia results in differential effects on apoptosis. Blood 1998; 92: 981–989
   PubMed Web of Science ®Google Scholar
• Amos T. A., Lewis J. L., Grand F. H., Gooding R. P., Goldman J. M., Gordon M. Y. Apoptosis in chronic myeloid leukemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br. J. Haematol. 1995; 91: 387–393
   PubMed Web of Science ®Google Scholar
• Albrecht T., Schwab R., Henkes M., Peshel C., Huber C., Aulitzky W. E. Primary immature myloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br. J. Haematol 1996; 95: 501–507
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2s compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 1994; 30: 820–825
   Google Scholar
• Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J. Natl. Cancer Inst. 1997; 89: 1616–1620
   PubMed Web of Science ®Google Scholar
• Geissler D., Gastl G., Aulitzky W., Tilg H., Gaggl S., Konwalinka G., Huber C. Recombinant inter-feron-alpha-2c in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response. Leuk. Res. 1990; 14: 629–636
   PubMed Web of Science ®Google Scholar
• Cornelissen J. J., Ploemacher R. E., Wognum B. W., Borsboom A., Kluin-Nelemans H. C., Hagemeijer A., Lowenberg B. An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture. J. Clin. Invest. 1998; 102: 976–983
   PubMed Web of Science ®Google Scholar
• Gordon M. Y., Marley S. B., Lewis J. L., Davidson R. J., Nguyen D. X., Grand F. H., Amos T. A., Goldman J. M. Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J. Clin. Invest. 1998; 102: 710–715
   PubMed Web of Science ®Google Scholar
• Bhatia R., McCarthy J. B., Verfaillie C. M. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996; 87: 3883–3891
   PubMed Web of Science ®Google Scholar
• Bhatia R., Verfaillie C. M. The effect of interferon-alpha on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia. Leuk. Lym-phoma 1998; 28: 241–254
   PubMed Web of Science ®Google Scholar
• Aman J. M., Keller U., Derigs G., Mohammadzadeh M., Huber C., Peschel C. Regulation of cytokine expression by interpheron alpha in human bone marrow stroma cells: inhibition of hematopoietic growth factors and induction of IL-1 receptor antagonist. Blood 1994; 84: 4142–4150
   PubMed Web of Science ®Google Scholar
• Bathia R., McGlave P., Verfaillie C M. Treatment of marrow stroma with interferon-α restores normal β1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1α. J. Clin. Invest. 1995; 96: 931–939
   PubMed Web of Science ®Google Scholar
• Wang C, Al-Omar H. M., Radvanyi L., Banerjee A., Bouman D., Squire J., Messner H. A. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha. Exp. Hematol. 1999; 27: 1176–1184
   PubMed Web of Science ®Google Scholar
• Nagata S. Apoptosis by death factor. Cell 1997; 88: 355–365
   PubMed Web of Science ®Google Scholar
• Chaudhuri A. R., Jeor S., St, Maciejewski J. P. Apoptosis induced by human cytomegalovirus infection can be enhanced by cytokines to limit the spread of virus. Exp. Hematol 1999; 27: 1194–1203
   PubMed Web of Science ®Google Scholar
• Maciejewski J. P., Selleri C., Anderson S., Young N. S. Fas antigen expression on CD34+human bone marrow cells is induced by interferon-γ and tumor necrosis factor-α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183–3190
   PubMed Web of Science ®Google Scholar
• Nagafuji K., Shibuya T, Harada M., Mizuno S., Takenaka K., Miyamoto T, Okamura T., Gondo H., Niho Y. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995; 86: 883–889
   PubMed Web of Science ®Google Scholar
• Sato T., Selleri C., Anderson S., Young N. S., Maciejewski J P. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br. J. Haematol 1997; 97: 356–365
   PubMed Web of Science ®Google Scholar
• Sato T., Selleri C., Young N. S., Maciejewski J. Hematopoietic inhibition by interferon-γ is partially mediated through interferon regulatory factor-1. Blood 1995; 86: 3373–3380
   PubMed Web of Science ®Google Scholar
• Peter M. E., Krammer P. H. Mechanisms of CD95(APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunol. 1998; 10: 545–551
   PubMed Web of Science ®Google Scholar
• Brenner B., Ferlinz K., Grassmé H., Weller K., Koppenhoefer U., Dichgans J., Sandhoff K., Lang F., Gulbins E. FAS/CD95/APO-1 activates the acidic sphingomyelinase via caspases. Cell Death Different. 1998; 5: 29–37
   PubMed Web of Science ®Google Scholar
• Selleri C., Sato T., Raiola A. M., Rotoli B., Young N. S., Maciejewski J. P. Induction of nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis in haemopoietic cells. Br. J. Haematol 1997; 99: 481–489
   PubMed Web of Science ®Google Scholar
• Miyamura K., Iijima N., Itou T., Tanimoto M., Saito H. Functional expression of Fas receptor on the progenitor cells of chronic myelogenous leukemia: induction by interferon-α, γ and ubemix. Blood 1996; 88: 232, (A). (suppl 1)
   Google Scholar
• Rizzoli V., Savoldo B., Regazzi E., Garau D., Sammarelli G., Mangoni L., Carlo Stella C. Chronic myelogenous leukemia CD34+ marrow cells lacking CD95 expression are enriched for BCR/ABL negative primitive and committed progenitors. Bone Marr. Transplant. 1997; 19: 30, (A) (suppl. 1)
   Google Scholar
• Pigeonnier-Lagarde V., Maguer-Satta V., Chachine H., Taupin F., Belloc J. L., Reiffers J., Mahon F. X. Expression of Fas antigen (CD95) on peripheral blood CD34+ chronic myeloid leukemia cells. Blood, 90: 281b, (A)
   Google Scholar
• Yotnda P., Firat H., Garcia-Pons F., Garcia Z., Gourru G., Vernant J. P., Lemonnier F. A., Leblond V., Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 1998; 101: 2290–2296
   PubMed Web of Science ®Google Scholar
• Osman Y., Takahashi M., Zheng Z., Koike T., Toba K., Liu A., Furukawa T., Aoki S., Aizawa Y. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 1999; 13: 166–174
   PubMed Web of Science ®Google Scholar
• Smit W. M., Rijnbeek M., Van Bergen C. A., Fibbe W. E., Willemze R., Falkenburg J. H. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc. Natl. Acad. Sci. USA 1998; 95: 10152–10157
   PubMed Web of Science ®Google Scholar
• Nagata S. Fas ligand and immune evasion. Nat. Med. 1996; 2: 1306–1307
   PubMed Web of Science ®Google Scholar
• Walker P. R., Saas P., Dietrich P-Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol 1998; 10: 564–572
   PubMed Web of Science ®Google Scholar
• Roger R., Issaad C., Pallardy M., Leglise M. C., Turhan A. G., Bertoglio J., Breard J. BCR-ABL does not prevent apoptotic cell death induced by human natural killer or lymphokine-activated killer cells. Blood 1996; 87: 1113–1122
   PubMed Web of Science ®Google Scholar
• Suda T, Hashimoto H., Tanaka M., Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 1997; 186: 2045–2050
   PubMed Web of Science ®Google Scholar
• Tanaka M., Itai T, Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat. Med. 1998; 4: 31–36
   PubMed Web of Science ®Google Scholar
• Amarante-Mendes G. P., Kim C. N., Liu L., Huang Y., Perkins C. L., Green D. R., Bhalla K. Bcr-Abl Exerts Its Antiapoptotic Effect Against Diverse Apoptotic Stimuli Through Blockage of Mitochondrial Release of Cytochrome C and Activation of Caspase-3. Blood 1998; 91: 1700–1705
   PubMed Web of Science ®Google Scholar
• Carlo Stella C., Regazzi E., Sammarelli G., Colla S., Garau D., Gazit A., Savoldo B., Cilloni D., Tabilio A., Levitzki A., Rizzoli V. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Blood 1999; 93: 3973–3982
   PubMed Web of Science ®Google Scholar
• Pane F, Mostarda I., Selleri C., Salzano R., Raiola A. M., Luciano L., Saglio G., Rotoli B., Salvatore F. Bcr/Abl mRNA and the 210bcr/abl protein are downmodulated by interferon-alpha in chronic myeloid leulemia patients. Blood 1999; 94: 2200–2207
   PubMed Web of Science ®Google Scholar
• Albitar H., Kantarijan T, Manshouri S., O'Brien S., Andreeff S., Kornblau S., Beran M, Keating M., Talpaz M. Expression of BCL-2 and FAS in chronic myelogenous leukemia (CML). Blood 1997; 88: 275b, (A). (suppl 1)
   Google Scholar